%0 Journal Article
%T 垂体腺瘤免疫治疗现状及进展<br>Current Status and Progress of Immunotherapy for Pituitary Adenoma
%A 田智杰
%A 张越林
%J Advances in Clinical Medicine
%P 4611-4615
%@ 2161-8720
%D 2021
%I Hans Publishing
%R 10.12677/ACM.2021.1110677
%X 垂体腺瘤是颅内一种常见的肿瘤，占颅内原发性肿瘤的10%~20%，垂体肿瘤在成人中发病率占第三位，仅次于脑胶质细胞瘤和脑膜瘤。目前手术、药物和放射治疗是垂体腺瘤治疗的三大重要治疗策略。然而垂体瘤易复发，控制欠佳，急需寻求新的治疗手段。肿瘤免疫治疗是一种很有前景的治疗方法，目前已应用于包括垂体肿瘤在内的多种肿瘤的治疗。本文通过回顾近年来国内外最新进展，我们总结了免疫检查点的最新发现及其作为垂体肿瘤免疫治疗靶点的潜力，以期为垂体腺瘤治疗提供一定的参考。<br />
Pituitary adenoma is a common intracranial tumor, which accounts for 10%~20% of the primary intracranial tumors. Pituitary adenoma is the third most common tumor in adults, next to glioma and meningioma. At present, surgery, drug therapy and radiotherapy are three important therapeutic strategies for pituitary adenomas. However, pituitary adenoma is easy to recur and has poor control, so it is urgent to seek new treatment. Tumor immunotherapy is a promising therapeutic method, which has been applied to a variety of tumors, including pituitary tumors. In this review, we summarize the latest findings of immunologic examination and site selection and their potential as immunotherapeutic targets for pituitary tumors in order to provide some references for the treatment of pituitary adenoma.
%K 垂体腺瘤，免疫检查点抑制剂，免疫治疗<br>Pituitary Adenoma
%K Immune Checkpoint Inhibitors
%K Immunotherapy
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=45875